CONSENSUS PAPER - LOW-DOSE CONTRACEPTIVE FORMULATIONS - IS FURTHER REDUCTION IN STEROID DOSAGE JUSTIFIED

被引:10
作者
ELSTEIN, M
机构
[1] Department of Obstetrics and Gynaecology, University Hospital of South Manchester, Manchester, M20 2LR, West Didsbury
关键词
D O I
10.1007/BF01986523
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Low-dosage hormonal contraceptives could be reduced to contain 20 μg ethinyl estradiol with the gonane progestogens. Available data demonstrate that preparations with sufficient gestodene and desogestrel adequately to suppress ovulation and prevent pregnancy are well tolerated. As long as the patient takes the tablets as prescribed, they should provide effective contraception. The advantages and benefits of hormonal contraception are likely to be retained. It is still necessary to identify women at risk of thromboembolism since the incidence might appear to be more related to susceptiblity than estrogen dosage. However, dosage may be related to the pathogenesis of thromboembolism. The crucial test of these new formulations will be the demonstration of adequate suppression of ovarian function with maintained contraceptive efficacy and concomitant good cycle control. © 1994 Kluwer Academic Publishers.
引用
收藏
页码:1 / 4
页数:4
相关论文
共 4 条
[1]  
Inman W.H.W., Vessey M.P., Westerholm B., Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs, Br Med J., 2, pp. 203-9, (1970)
[2]  
Bye P.G.T., Elstein M., Clinical assessment of a low-dose combined oral contraceptive, Br Med J., 2, pp. 389-92, (1973)
[3]  
Morris S.E., Groom G.V., Cameron E.D., Buckingham, Everitt J.M., Elstein M., Studies on low dose contraceptives: plasma hormone changes in relation to deliberate pill (microgynon 30) omission, Contraception., 20, pp. 61-9, (1979)
[4]  
Killick S.R., Bancroft K., Oelbaum S., Morris J., Elstein M., Extending the duration of the pill-free interval during combined oral contraception, Adv Contracept., 6, pp. 33-40, (1990)